China-based biopharmas have raised collective $4.1B in IPOs this year: Data Byte

Sixteen Chinese biopharmas have raised a combined total of over $4.1 billion across IPOs on NASDAQ, the Hong Kong stock exchange and Shanghai’s STAR board in 2021, according to BioCentury’s BCIQ database, putting the industry on track with 2020 IPO financings. 

The most recent came this week from Brii Biosciences (HKEX:2137), which raised nearly HK$2.5 billion ($319.6 million) to support a dozen clinical programs in the U.S. and China. ...